top of page

MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative

– Oversubscribed Series B round led by TPG includes prominent group of new and existing investors, bringing total raised to-date to over $110 million

– Funding supports rapid clinical development of targeted ADC therapeutics in difficult-to-treat cancers

– Chris LeMasters joins as Independent Board Member, bringing 25 years of biotech experience



Recent Posts

See All

Comments


© 2020 by Chang-Han Lee of Site (Antibody engineering | TheLeeLab_SNU_MED). 

bottom of page